There are 2867 resources available
829P - A proof of concept study of sequential treatment with the HDAC inhibitor vorinostat plus BRAF and MEK inhibitors in BRAFV600 mutated melanoma
Presenter: Alaa Embaby
Session: Poster session 03
1513P - Impact of mutational status on long-term treatment outcomes in patients with advanced gastrointestinal stromal tumors (GIST) treated in the first line with imatinib
Presenter: Pawel Sobczuk
Session: Poster session 11
1102P - Genomic alterations correlated with the expression of PD-L1 based on the next-generation sequencing in Chinese non-small cell lung cancer
Presenter: xiaoping Li
Session: Poster session 15
830P - Efficacy of immunotherapy in melanoma patients with symptomatic brain metastases treated with steroids: Initial report from the MEMBRAINS trial
Presenter: Troels Borch
Session: Poster session 03
1514P - Anti-tumor effects of the novel KIT mutant inhibitor M4205 in gastrointestinal stromal tumor (GIST) xenograft models
Presenter: Luna De Sutter
Session: Poster session 11
1103P - Drug-related pneumonitis induced by osimertinib as first-line treatment for EGFR-positive non-small cell lung cancer: A real-world setting
Presenter: Yuki Sato
Session: Poster session 15
831P - Outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp
Presenter: Erica Koch
Session: Poster session 03
1515P - Nationwide management of soft tissue sarcoma (STS) in France, before (2019) versus during COVID-19 pandemic (2020)
Presenter: Nicolas Penel
Session: Poster session 11
1104P - Health-related quality of life (HRQOL) in patients with ALK+ non-small cell lung cancer (NSCLC) in the phase III CROWN study
Presenter: Geoffrey Liu
Session: Poster session 15
832P - Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)
Presenter: Florentia Dimitriou
Session: Poster session 03